Clinical trial
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or…
NCT00015912 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00015912 |
|---|---|
| Title | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC #66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | recombinant interferon alfa, thalidomide, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Jul 1, 2001 |
| Primary completion | Sep 1, 2003 |
| First posted | Oct 15, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: